Dexcom has announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1.

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

Analysts are intrested in these 5 stocks: ( ($NOW) ), ( ($DXCM) ), ( ($COIN) ), ( ($JMIA) ) and ( ($KEYS) ). Here is a breakdown of their recent ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. U.S. large-cap growth ...

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

DexCom recently announced the upcoming U.S. launch of its G7 15 Day Continuous Glucose Monitoring system and received FDA clearance for its Smart Basal insulin dosing optimizer, both targeting ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

NEW YORK, NY / ACCESS Newswire / November 27, 2025 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter ...

November is National Diabetes Month, and Durango's Bruce Moss is proving diabetes doesn’t have to slow you down. At 67, he ...

Labaton Keller Sucharow LLP ("Labaton") announces that, on November 25, 2025, it filed a securities class action lawsuit (the "Complaint") on behalf of its client Boston Retirement System ("Boston") ...

The bull case for DexCom is that the company continues to grow and has a lot of room to grow more. The bear case for the stock is that DexCom's sky-high valuation may be hard to justify in the long ...